Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Anavex Life Sciences Corp.NASDAQ: AVXL

Stock-Based Compensation · Q1 FY2026 · quarter ended Dec 2025

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $1.11M fell 46.1% year over year, behind the +15.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 70.2% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -46.1% toward the trailing-twelve-month pace of +15.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.11M-70.2% QoQ
Last fiscal yearSep 2025
$11.55M+22.4% YoY
LTMDec 2025
$10.6M+15.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-46.1%——
1 year+22.4%——
3-year CAGR-14.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.55M USD
Year-over-year change
+22.4%
4-year CAGR
+8.8%

Stock-Based Compensation vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.1% is the 6th highest of 9, against a peer median of +29.2%.
  • Over three fiscal years its annual growth of -14.3% compares with a peer median of +1.0%.
AVXL Competitors
Stock-Based Compensation for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M USD+107.3%-8.3%60.1%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$41.75M USD+456.0%+204.9%—
ERASErasca, Inc.LTM Sep 2026$35.82M USD+41.1%+7.4%—
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M USD-7.4%-5.4%39.4%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$23.96M USD+203.5%+10.1%—
ARVNArvinas, Inc.LTM Mar 2026$18.8M USD-77.8%-16.5%21.0%
ABSIAbsci CorporationLTM Mar 2026$13.53M USD-11.4%+13.5%737.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$10.6M USD+15.1%-14.3%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$9.12M USD+17.3%-21.7%25.6%
VALNValneva SELTM Mar 2026€0 EUR——0.0%
Peer median (excluding AVXL) —+29.2%+1.0%32.5%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation8.23M18.38M16.37M9.44M11.55M
Change in Working Capital(706K)5.36M2.51M2.75M(4.22M)
Accounts Receivables(4.29M)5.94M484K260K1.64M
Inventory00000
Accounts Payables751K(914K)497K5.31M(5.38M)
Other Working Capital2.83M331K1.52M(2.81M)(478K)
Other Non-Cash Items00845K00
Operating Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued153.22M22M29.65M11.98M12.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities24K(707K)29.65M11.98M(2.71M)
Financing Cash Flow153.24M21.29M29.65M11.98M9.43M
Effect of Forex Changes00000
Net Change in Cash122.86M(2.95M)1.87M(18.84M)(29.61M)
Free Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.